We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis.
- Authors
Cerrano, Marco; Chevret, Sylvie; Raffoux, Emmanuel; Rabian, Florence; Sébert, Marie; Valade, Sandrine; Itzykson, Raphael; Lemiale, Virginie; Adès, Lionel; Boissel, Nicolas; Dombret, Hervé; Azoulay, Elie; Lengliné, Etienne
- Abstract
Hyperleukocytosis is associated with a significant early mortality rate in patients with acute myeloid leukemia (AML). To date, no controlled trial has ever evaluated a strategy to reduce this risk, and the initial management of these patients remains heterogeneous worldwide. The aim of the present study was to evaluate the influence of a short course of intravenous dexamethasone on the early outcomes of patients with hyperleukocytic AML with white blood cell (WBC) count above 50 × 109/L. Clinical and biological data of all consecutive patients (1997–2017) eligible for intensive chemotherapy from a single center were retrospectively collected. A total of 251 patients with a median age of 51 years and a median WBC count of 120 × 109/L were included, 95 of whom received dexamethasone. Patients treated with dexamethasone had higher WBC count and a more severe disease compared with those who did not, and they presented more often with leukostasis and hypoxemia, resulting in a more frequent need for life-sustaining therapies (p < 0.001). To account for these imbalances, patients were compared after adjusting for a propensity score, which included all variables with a prognostic influence in the overall cohort. In the matched cohort, dexamethasone was associated with lower early death (OR = 0.34, p = 0.0026) and induction failure rate (OR = 0.44, p = 0.02) and better overall survival (HR = 0.60, p = 0.011), with no impact on relapse risk (cHR = 0.73, p = 0.39). The overall survival benefit was confirmed among all tested subgroups. This study suggests that dexamethasone administration is safe and associated with a lower risk of induction mortality in patients with hyperleukocytic AML and deserves prospective evaluation.
- Subjects
ACUTE myeloid leukemia; PROPENSITY score matching; LEUKAPHERESIS; LEUCOCYTES; DEXAMETHASONE; TREATMENT effectiveness
- Publication
Annals of Hematology, 2023, Vol 102, Issue 4, p761
- ISSN
0939-5555
- Publication type
Article
- DOI
10.1007/s00277-023-05119-3